Renpho

Biotech Longeveron files for $30M IPO

Latest articles

The Sheekey Science Show: NAD+ rejuvenation strategies

NAD+ metabolism in aging & three strategies to rejuvenate. Welcome to The Sheekey Science Show! Longevity.Technology is delighted to partner with YouTube sensation Eleanor Sheekey (interviewed...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

BioAge kicks off Phase 2 longevity clinical trial

Company reveals primary indicator for BGE-117 clinical trial is unexplained anaemia of aging. Hot on the heels of its monster $90 million Series C funding...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Apollo Neuro

Editor's picks

The Sheekey Science Show: NAD+ rejuvenation strategies

NAD+ metabolism in aging & three strategies to rejuvenate. Welcome to The Sheekey Science Show! Longevity.Technology is delighted to partner with YouTube sensation Eleanor Sheekey (interviewed...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...
Renpho

Florida-based Longeveron files for a $30 million IPO, targeting aging-related conditions.

Longeveron, a Phase 2 biotech which develops cellular therapies for aging-related conditions, filed the first longevity biotech IPO of 2021 with the US Securities and Exchange Commission (SEC) earlier this month to raise up to $30 million in an initial public offering.

Longevity.Technology: Longeveron, which is based in Miami, is a clinical-stage biotech, which is developing cellular therapies with the aim of tackling specific aging-related, life-limiting and life-threatening conditions. Its lead investigational product is Lomecel-B; this is a cell-based therapy derived from culture-expanded medicinal signalling cells which have been sourced from the bone marrow of young, healthy, adult donors.

In addition, the company is currently sponsoring Phase I and II trials in Alzheimer’s disease, aging frailty, metabolic syndrome, Acute Respiratory Distress Syndrome (ARDS) and hypoplastic left heart syndrome.

In June the company announced a Phase II clinical trial to evaluate the safety and efficacy of Mesenchymal Stem Cells (LMSCs) for the treatment of aging frailty in Japanese patients.

 


 

The company has booked $6 million in revenue for the 12 months period to September 2020 and plans to list on the Nasdaq under the symbol LGVN.

 


 

Longeveron was founded in 2014 by Donald Soffer and Joshua Hare. Following a seed round in autumn 2017 which raised nearly $3m, Longeveron has received funding from several grants, including $3,8m from National Institutes of Health in October 2018 and $3m from the Alzheimer’s Association in July 2019.

The company has booked $6 million in revenue for the 12 months period to September 2020 and plans to list on the Nasdaq under the symbol LGVN. Longeveron filed confidentially in November of last year with Kingswood Capital Markets as the sole bookrunner on the deal. No pricing terms have yet been disclosed.

Mesenchymal Stem Cells research has other interests in the space; Mesoblast announced an exclusive worldwide licence and collaboration with Novartis for the development, manufacture and commercialisation of their MSC product remestemcel-L, with an initial focus on COVID-19 and ARDS.

In addition, Cellular Biomedicine Group, Inc, is developing allogeneic human adipose-derived MSC therapy, with phase II clinical trials in osteoarthritis underway and plans for a phase II trial for knee osteoarthritis, and Athersys, Inc‘s MultiStem clinical product is in phase III for ischemic stroke, and is, the company claims, the only investigational cell therapy for the treatment of ARDS that has been granted both Fast Track and RMAT designation by the FDA.

Image credit: Pavel Ignatov / Shutterstock
Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
Renpho

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...

It’s time to sit up and take notice of mitochondria

CohBar CEO on the development of a “true portfolio” of mitochondria based therapeutics. US biotech company CohBar is developing mitochondria-based therapeutics for the treatment of...
Apollo Neuro

Related articles

Leading NAD+ company ChromaDex announces $25m raise

LA-based company ChromaDex announces that it has entered into a securities purchase agreement for the sale of $25m of its common stock in a...

Andreessen Horowitz leads $7m seed funding: Bold

Digital health and wellness company bags $7 million in seed funding led by Andreessen Horowitz. Bold focuses on disease prevention and healthy aging. Using personalised and...

Charles River to acquire Cognate BioServices for $875m

Charles River Laboratories signs $875 million cash deal to acquire cell and gene manufacturer Cognate BioServices. Charles River has announced plans to acquire Cognate BioServices,...

Life Biosciences in-licenses IP from new studies

Studies "open a new frontier in biotechnology and medicine," says Life Biosciences CEO. Intellectual property generated by the scientific findings behind two recent publications in...

$1.1B biotech SPAC good news for longevity

Bioengineered human tissue company Humacyte nears biotech SPAC deal to go public. Humacyte, a transformative biotech platform company capable of manufacturing universally-implantable bioengineered human tissue...
TruNigen pf